| Literature DB >> 23554551 |
Harold I Zeliger1, Yaqin Pan, William J Rea.
Abstract
The exhaled breath of more than four hundred patients who presented at the Environmental Health Center - Dallas with chemical sensitivity conditions were analyzed for the relative abundance of their breath chemical composition by gas chromatography and mass spectrometry for volatile and semi-volatile organic compounds. All presenting patients had no fewer than four and as many as eight co-morbid conditions. Surprisingly, almost all the exhaled breath analyses showed the presence of a preponderance of lipophilic aliphatic and aromatic hydrocarbons. The hydrophilic compounds present were almost entirely of natural origin, i.e. expected metabolites of foods. The lipophile, primarily C3 to C16 hydrocarbons and believed to have come from inhalation of polluted air, were, in all cases, present at concentrations far below those known to be toxic to humans, but caused sensitivity and signs of chemical overload. The co-morbid health effects observed are believed to be caused by the sequential absorption of lipophilic and hydrophilic chemicals; an initial absorption and retention of lipophile followed by a subsequent absorption of hydrophilic species facilitated by the retained lipophile to produce chemical mixtures that are toxic at very low levels. It is hypothesized that co-morbid conditions in chemically sensitive individuals can be predicted from analysis of their exhaled breath.Entities:
Keywords: chemical mixtures; chemical sensitivity; exhaled breath analysis; sequential absorption; toxic chemicals
Year: 2012 PMID: 23554551 PMCID: PMC3600511 DOI: 10.2478/v10102-012-0020-7
Source DB: PubMed Journal: Interdiscip Toxicol ISSN: 1337-6853
Relative abundance of breath toxins found in 30 chemically sensitive patients. Data in parts per billion (ppb).
| Less Polluted Room Ambient | ||||
|---|---|---|---|---|
| PT # | Breath | Alveolar | Air | Impacts |
| 1 | 7.6 | 2.6 | 4.8 | left |
| 2 | 55.0 | 52.5 | 2.1 | NS IM CV CS |
| 3 | 11.3 | 4.2 | 5.6 | AL NS IM MK HR CS |
| 4 | 563.2 | 499.0 | 64.2 | NS IM CV GI CS |
| 5 | 529.1 | 480.9 | 47.8 | AL NS IM MK CV GI RS FR CS |
| 6 | 1486.8 | 1420.4 | 54.2 | AL NS IM GI RS CS |
| 7 | 838.2 | 701.1 | 134.9 | AL NS IM CV GI CS RS UR |
| 8 | 1257.4 | 1176.4 | 78.5 | AL NS IM CV GI RS CS |
| 9 | 135.2 | 128.7 | 6.4 | left RS |
| 10 | 149.8 | 74.9 | 75.3 | AL NS IM CV GI CS RS |
| 11 | 615.5 | 539.7 | 73.8 | AL NS IM GI RS CS |
| 12 | 21.2 | 13.4 | 7.6 | AL NS IM CV RS CS |
| 13 | 839.6 | 749.9 | 89.6 | AL NS IM MK CV GI RS CS |
| 14 | 925.1 | 818.8 | 113.4 | AL NS IM CV RS CS |
| 15 | 156.0 | 151.8 | 6.0 | AL NS IM CV CS RS |
| 16 | 309.1 | 306.4 | 5.7 | AL NS IM GI RS HR CS |
| 17 | 447.7 | 427.7 | 25.1 | AL NS IM MK RS CS |
| 18 | 374.8 | 364.5 | 10.9 | AL NS IM CV GI RS CS |
| 19 | 35.6 | 33.7 | 1.0 | AL NS IM MK CV GI CS RS |
| 20 | 310.9 | 282.2 | 14.7 | AL NS IM CV GI DR RS CS |
| 21 | 462.7 | 27.2 | 1.8 | AL NS IM CV GI RS CS |
| 22 | 131.8 | 1.3 | 1.0 | AL NS IM MK GI RS CS |
| 23 | 528.1 | 478.7 | 17.8 | AL NS IM CV GI RS CS |
| 24 | 85.8 | 76.7 | 9.2 | AL NS IM SK DR RS CS |
| 25 | 2.6 | 1.1 | 1.5 | AL NS IM CV GI RS CS |
| 26 | 11.8 | 1.1 | 2.5 | AL NS IM CV GI RS CS |
| 27 | 11.8 | 7.1 | 4.3 | AL NS IM CV GI RS CS |
| 28 | 41.2 | 38.6 | 2.2 | AL NS IM CV GI RS CS |
| 29 | 68.3 | 64.2 | 7.5 | AL NS IM GI RS CS |
| 30 | 60.2 | 50.1 | 9.0 | AL NS IM CV GI RS CS |
AL = Allergic sensitivity; CS = Chemical sensitivity; CV = Cardiovascular effects; DR = Dermal effects; GI = Gastrointestinal effects; IM = Immune system impact effects; MK = Musculoskeletal effects; NS = Nervous system effects; RS = Upper and lower respiratory system effects
All patients had chemical sensitivities
Multiple systems involved in chemically sensitive patients.
| # Systems Impacted | # of People |
|---|---|
| 4 | 2 |
| 5 | 5 |
| 6 | 9 |
| 7 | 10 |
| 8 | 3 |
| 9 | 1 |
Number and percentage of individuals for each affected system.
| System | # of People | % |
|---|---|---|
| Nervous | 30 | 100 |
| Immune | 30 | 100 |
| Chemical sensitivity | 30 | 100 |
| Allergic responses | 28 | 93 |
| Respiratory | 25 | 83 |
| Cardiovascular | 23 | 77 |
| Gastrointestinal | 23 | 77 |
| Musculoskeletal | 10 | 33 |
| EMF sensitivity | 5 | 17 |
| Hormonal | 3 | 10 |
| Dermal | 2 | 7 |
| Female reproductive | 2 | 7 |
| Urinary track | 1 | 3 |
| Tumor | 1 | 3 |